Optimizing timing of adolescent vaccines: Impact of initiating HPV vaccination before Tdap or meningococcal vaccination on timely completion of the HPV vaccine series

References

• Schiffman MH, Castle P. Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst. 2003;95(6):E2. doi:10.1093/jnci/95.6.E2.
   PubMedGoogle Scholar
• Senkomago V, Henley SJ, Thomas CC, Mix JM, Markowitz LE, Saraiya M. Human papillomavirus-attributable cancers - United States, 2012-2016. MMWR. 2019;68(33):724–8. doi:10.15585/mmwr.mm6833a3.
   PubMed Web of Science ®Google Scholar
• Demarco M, Hyun N, Carter-Pokras O, Raine-Bennett TR, Cheung L, Chen X, Hammer A, Campos N, Kinney W, Gage JC, et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020;22:100293. doi:10.1016/j.eclinm.2020.100293.
   PubMedGoogle Scholar
• Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow S-N, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–14. doi:10.1016/S0140-6736(09)61248-4.
   PubMed Web of Science ®Google Scholar
• Group FIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–27. doi:10.1056/NEJMoa061741.
   PubMed Web of Science ®Google Scholar
• Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, Sundström K, Dillner J, Sparén P. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340–48. doi:10.1056/NEJMoa1917338.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Bryant A, Beutels P, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2011;2011(4):CD009069. doi:10.1002/14651858.CD009069.
   PubMedGoogle Scholar
• Kjaer SK, Dehlendorff C, Belmonte F, Baandrup L. Real-world effectiveness of human papillomavirus vaccination against cervical cancer. J Natl Cancer Inst. 2021;113(10):1329–35. doi:10.1093/jnci/djab080.
   PubMedGoogle Scholar
• Mix JM, Van Dyne EA, Saraiya M, Hallowell BD, Thomas CC. Assessing impact of HPV vaccination on cervical cancer incidence among women aged 15-29 years in the United States, 1999-2017: an ecologic study. Cancer Epidemiol, Biomarkers Prev. 2021;30(1):30–37. doi:10.1158/1055-9965.EPI-20-0846.
   PubMed Web of Science ®Google Scholar
• Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, Elliss-Brookes L, Sasieni P. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084–92. doi:10.1016/S0140-6736(21)02178-4.
   PubMed Web of Science ®Google Scholar
• Krajden M, Cook D, Yu A, Chow R, Mei W, McNeil S, Money D, Dionne M, Karunakaran KP, Palefsky JM, et al. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol. 2011;18(3):418–23. doi:10.1128/CVI.00489-10.
   PubMedGoogle Scholar
• Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. Jama. 2013;309(17):1793–802. doi:10.1001/jama.2013.1625.
   PubMed Web of Science ®Google Scholar
• Perkins RB, Lin M, Wallington SF, Hanchate A. Impact of number of human papillomavirus vaccine doses on genital warts diagnoses among a national cohort of U.S. adolescents. Sex Transm Dis. 2017;44(6):365–70. doi:10.1097/OLQ.0000000000000615.
   PubMed Web of Science ®Google Scholar
• Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11(1):227. doi:10.1186/1741-7015-11-227.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Nygård M, Dillner J, Brooke Marshall J, Radley D, Li M, Munk C, Hansen BT, Sigurdardottir LG, Hortlund M, et al. A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries. Clin Infect Dis. 2018;66(3):339–45. doi:10.1093/cid/cix797.
   PubMed Web of Science ®Google Scholar
• Porras C, Tsang SH, Herrero R, Guillén D, Darragh TM, Stoler MH, Hildesheim A, Wagner S, Boland J, Lowy DR, et al. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. Lancet Oncol. 2020;21(12):1643–52. doi:10.1016/S1470-2045(20)30524-6.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on Immunization practices (ACIP). MMWR Recomm Rep. 2007;56:1–24.
   PubMedGoogle Scholar
• Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, Bocchini JA, Unger ER. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR–05):1–30.
   PubMed Web of Science ®Google Scholar
• Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. MMWR. 2019;68(32):698–702. doi:10.15585/mmwr.mm6832a3.
   PubMed Web of Science ®Google Scholar
• ACIP. Recommendations on the use of quadrivalent human papillomavirus vaccine in males–advisory Committee on Immunization Practices (ACIP),2011. MMWR. 2011;60(50):1705–08.
   PubMedGoogle Scholar
• CDC. 5 ways to boost your HPV vaccination rates. Published online November 1, 2021. [accessed 2023 Jan 9]. https://www.cdc.gov/hpv/hcp/boosting-vacc-rates.html.
   Google Scholar
• Accountable Health Partners. ADOLESCENT IMMUNIZATION (Combo #2) (2020 MEASURE v4.202020). [accessed 2022 Sep 28]. https://ahpnetwork.com/wp-content/uploads/2020/05/Adol_Imm_Combo2_v2.6.pdf.
   Google Scholar
• Pingali C, Yankey D, Elam-Evans LD, Markowitz LE, Valier MR, Fredua B, Crowe SJ, Stokley S, Singleton JA. National vaccination coverage among adolescents aged 13–17 years — national immunization survey-teen, United States, 2021. MMWR. 2022;71(35):1101–08. doi:10.15585/mmwr.mm7135a1.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. ACS updates HPV vaccination recommendations to start at age 9. Published online 2020. [accessed 2022 Sep 28]. https://www.cancer.org/latest-news/acs-updates-hpv-vaccination-recommendations-to-start-at-age-9.html.
   Google Scholar
• American Academy of Pediatrics Committee on. Why AAP recommends initiating HPV vaccination as early as age 9. Published online 2019. [accessed 2022 Sep 28]. https://publications.aap.org/aapnews/news/14942?autologincheck=redirected?nfToken=00000000-0000-0000-0000-000000000000.
   Google Scholar
• St Sauver JL, Rutten LJF, Ebbert JO, Jacobson DJ, McGree ME, Jacobson RM. Younger age at initiation of the human papillomavirus (HPV) vaccination series is associated with higher rates of on-time completion. Prev Med. 2016;89:327–33. doi:10.1016/j.ypmed.2016.02.039.
   PubMed Web of Science ®Google Scholar
• Perkins RB, Legler A, Jansen E, Bernstein J, Pierre-Joseph N, Eun TJ, Biancarelli DL, Schuch TJ, Leschly K, Fenton ATHR, et al. Improving HPV vaccination rates: a stepped-wedge randomized trial. Pediatrics. 2020;146(1). doi:10.1542/peds.2019-2737.
   PubMed Web of Science ®Google Scholar
• Goleman MJ, Dolce M, Morack J. Quality improvement initiative to improve human papillomavirus vaccine initiation at 9 years of age. Acad Pediatr. 2018;18(7):769–75. doi:10.1016/j.acap.2018.05.005.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Smith PJ, Hill HA. Evaluation of potentially achievable vaccination coverage with simultaneous administration of vaccines among children in the United States. Vaccine. 2016;34(27):3030–36. doi:10.1016/j.vaccine.2016.04.097.
   PubMed Web of Science ®Google Scholar
• Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kang Y. Vaccination coverage among children aged 19–35 months — United States, 2017. MMWR. 2018;67(40):1123–28. doi:10.15585/mmwr.mm6740a4.
   PubMed Web of Science ®Google Scholar
• Stokley S, Kempe A, Stockwell MS, Szilagyi PG. Improving pediatric vaccination coverage in the United States. Acad Pediatr. 2021;21(4S):S1–2. doi:10.1016/j.acap.2021.03.004.
   PubMedGoogle Scholar
• CDC. Child and adolescent Immunization Schedule. [accessed 2022 Sep 28]. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html#birth-15.
   Google Scholar
• Fenton ATHR, Eun TJ, Clark JA, Perkins RB. Calling the shots? Adolescents’ influence on human papillomavirus vaccine decision-making during clinical encounters. J Adolesc Health. 2020;66(4):447–54. doi:10.1016/j.jadohealth.2019.10.020.
   PubMed Web of Science ®Google Scholar
• Biancarelli DL, Drainoni ML, Perkins RB. Provider Experience Recommending HPV Vaccination Before Age 11 Years. J Pediatr. 2019 Nov 19;217:92–97. doi:10.1016/j.jpeds.2019.10.025.
   PubMed Web of Science ®Google Scholar
• Fisher-Borne M, Preiss AJ, Black M, Roberts K, Saslow D. Early outcomes of a multilevel human papillomavirus vaccination pilot intervention in federally qualified health centers. Acad Pediatr. 2018;18(2S):S79–84. doi:10.1016/j.acap.2017.11.001.
   PubMed Web of Science ®Google Scholar
• Perkins RB, Foley S, Hassan A, Jansen E, Preiss S, Isher-Witt J, Fisher-Borne M. Impact of a multilevel quality improvement intervention using national partnerships on human papillomavirus vaccination rates. Acad Pediatr. 2021;21(7):1134–41. doi:10.1016/j.acap.2021.05.018.
   PubMed Web of Science ®Google Scholar
• Chan JK, Mann AK, Lee D, Rohatgi A, Chan C, Abel MK, Argueta C, Kapp DS. Human papillomavirus vaccination trends and disparities in the United States: who is getting left behind? Sex Transm Dis. 2021;48(10):714–19. doi:10.1097/OLQ.0000000000001410.
   PubMed Web of Science ®Google Scholar
• Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature. Hum Vaccines Immunother. 2019;15(1):146–55. doi:10.1080/21645515.2018.1512453.
   PubMed Web of Science ®Google Scholar
• Kempe A, O’leary ST, Markowitz LE, Crane LA, Hurley LP, Brtnikova M, Beaty BL, Meites E, Stokley S, Lindley MC. HPV vaccine delivery practices by primary care physicians. Pediatr. 2019;144(4):e20191475. doi:10.1542/peds.2019-1475.
   PubMed Web of Science ®Google Scholar
• Finney Rutten LJ, St Sauver JL, Beebe TJ, Wilson PM, Jacobson DJ, Fan C, Breitkopf CR, Vadaparampil ST, MacLaughlin KL, Jacobson RM. Association of both consistency and strength of self-reported clinician recommendation for HPV vaccination and HPV vaccine uptake among 11- to 12-year-old children. Vaccine. 2017;35(45):6122–28. doi:10.1016/j.vaccine.2017.09.056.
   PubMed Web of Science ®Google Scholar
• Bynum SA, Staras SAS, Malo TL, Giuliano AR, Shenkman E, Vadaparampil ST. Factors associated with medicaid providers’ recommendation of the HPV vaccine to low-income adolescent girls. J Adolesc Health. 2014;54(2):190–96. doi:10.1016/j.jadohealth.2013.08.006.
   PubMed Web of Science ®Google Scholar
• Nasim U, Morgan ZJ, Peterson LE. The declining scope of practice of family physicians is limited to urban areas. J Rural Health. 2021;37(4):734–44. doi:10.1111/jrh.12540.
   PubMed Web of Science ®Google Scholar
• immunize.org. State laws and mandates by vaccine state mandates on immunization and vaccine-preventable diseases. [accessed 2022 Jan 20]. https://www.immunize.org/laws/.
   Google Scholar
• Tiro JA, Pruitt SL, Bruce CM, Persaud D, Lau M, Vernon SW, Morrow J, Skinner CS. Multilevel correlates for human papillomavirus vaccination of adolescent girls attending safety net clinics. Vaccine. 2012;30(13):2368–75. doi:10.1016/j.vaccine.2011.11.031.
   PubMed Web of Science ®Google Scholar
• Constable C, Ferguson K, Nicholson J, Quinn GP. Clinician communication strategies associated with increased uptake of the human papillomavirus (HPV) vaccine: a systematic review. CA Cancer J Clin. 2022;72(6):561–69. doi:10.3322/caac.21753.
   PubMed Web of Science ®Google Scholar
• Opel DJ, Mangione-Smith R, Robinson JD, Heritage J, DeVere V, Salas HS, Zhou C, Taylor JA. The influence of provider communication behaviors on parental vaccine acceptance and visit experience. Am J Public Health. 2015;105(10):1998–2004. doi:10.2105/AJPH.2014.302425.
   PubMed Web of Science ®Google Scholar
• Fenton AT, Eun TJ, Clark JA, Perkins RB. Indicated or elective? The association of providers’ words with HPV vaccine receipt. Hum Vaccines Immunother. 2018 May 30; 1–7. 10.1080/21645515.2018.1480237.
   PubMed Web of Science ®Google Scholar
• Gilkey MB, Calo WA, Moss JL, Shah PD, Marciniak MW, Brewer NT. Provider communication and HPV vaccination: the impact of recommendation quality. Vaccine. 2016;34(9):1187–92. doi:10.1016/j.vaccine.2016.01.023.
   PubMed Web of Science ®Google Scholar
• Horný M, Morgan JR, Merker VL. Using medical claims for policy effectiveness surveillance: reimbursement and utilization of abdomen/pelvis computed tomography scans. Health Serv Res. 2015;50(6):1910–26. doi:10.1111/1475-6773.12293.
   PubMed Web of Science ®Google Scholar
• Casey SM, Jansen E, Drainoni ML, Schuch TJ, Leschly KS, Perkins RB. Long-term multilevel intervention impact on human papillomavirus vaccination rates spanning the COVID-19 pandemic. J Low Genit Tract Dis. 2022;26(1):13–19. doi:10.1097/LGT.0000000000000648.
   PubMed Web of Science ®Google Scholar
• Szilagyi PG The HPV 9-10 trial: earlyinitiation of HPV vaccination. https://clinicaltrials.gov/ct2/show/NCT04722822?term=Szilagyi&cond=HPV&draw=2&rank=9.
   Google Scholar